Lv11
10 积分 2024-03-02 加入
ABS0277 DISCOVERY AND CHARACTERIZATION OF SIM0711, A POTENT AND SELECTIVE IRAK4 PROTAC WITH ENHANCED EFFICACY AND SAFETY
2小时前
求助中
Switching off autoimmunity
1个月前
已完结
The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects
1个月前
已完结
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis
1个月前
已完结
Disease modification in inflammatory skin disorders: opportunities and challenges
1个月前
已完结
Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
1个月前
已完结
Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis
1个月前
已完结
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
1个月前
已完结
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
1个月前
已完结
皖公网安备34019202002308
